01/08/2025
Anti-CGRP monoclonal antibodies were not associated with higher CVD risks compared to onabotulinumtoxinA in Medicare beneficiaries with migraine, a group who were predominantly older adults or disabled. https://ja.ma/4a1Udmi
JAMA Neurology is a member of the JAMA Network, a consortium of peer-reviewed publications.
330 N Wabash Avenue
Chicago, IL
60611
Be the first to know and let us send you an email when JAMA Neurology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to JAMA Neurology: